{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T21:51:47Z","timestamp":1768773107266,"version":"3.49.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2016,4,22]],"date-time":"2016-04-22T00:00:00Z","timestamp":1461283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Pink Agenda"},{"DOI":"10.13039\/100006258","name":"LIVESTRONG Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006258","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Susan G. Komen Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>Cardiotoxicity can be a complication of anthracycline- or trastuzumab-based therapy for breast cancer patients. Screening echocardiograms (ECHOs) and radionuclide ventriculograms (RVGs) are often performed before administration of these agents to evaluate cardiac function. Limited evidence for the clinical utility of these screening tests is available.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods.<\/jats:title>\n                  <jats:p>Early-stage breast cancer patients diagnosed from 2006 to 2011 (n = 1,067) with baseline ECHOs\/RVGs were identified in a single institution prospective registry. Medical record review was performed to obtain pre- and post-ECHO\/RVG treatment plans, baseline ECHO\/RVG results, cardiac risk factors, and cardiac events. Patients with cardiac history were excluded. ECHO\/RVG abnormalities were defined as ejection fraction (EF) &amp;lt;55%, valvular disease, left ventricular hypertrophy, and diastolic dysfunction. Cardiac events were defined as heart failure, myocardial infarction, arrhythmia, valvular disease, or angina during or after chemotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>Among 600 eligible patients, abnormal ECHO\/RVG results were observed in 13 (2.2%, 1.2%\u20133.7%), including 9 with baseline EF &amp;lt;55%. There were no detected changes in treatment plans, although more frequent cardiac monitoring was recommended for 2 patients. There were no significant differences in age, race, menopausal status, smoking history, alcohol use, body mass index, or medical comorbidities between patients with abnormal and normal results. In follow-up (mean, 4.0 years; range, 0\u20138.3), 15 patients developed cardiac events (none of whom had had abnormal baseline ECHOs\/RVGs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>Baseline ECHO\/RVG in patients without prior cardiac history rarely yields an abnormality that prompts change in planned anthracycline- and\/or trastuzumab-based treatment. Moreover, few cardiac events developed in this screened population in follow-up.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2015-0449","type":"journal-article","created":{"date-parts":[[2016,4,23]],"date-time":"2016-04-23T03:38:31Z","timestamp":1461382711000},"page":"666-670","source":"Crossref","is-referenced-by-count":18,"title":["Evaluating the Utility of Baseline Cardiac Function Screening in Early-Stage Breast Cancer Treatment"],"prefix":"10.1093","volume":"21","author":[{"given":"Sandy R.","family":"Truong","sequence":"first","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William T.","family":"Barry","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javid J.","family":"Moslehi","sequence":"additional","affiliation":[{"name":"School of Medicine, Vanderbilt University, Nashville, Tennessee, USA"},{"name":"Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily L.","family":"Baker","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica L.","family":"Mayer","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann H.","family":"Partridge","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,4,22]]},"reference":[{"key":"2021122309534833300_B1","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/cncr.10854","article-title":"Trastuzumab-associated cardiotoxicity","volume":"95","author":"Keefe","year":"2002","journal-title":"Cancer"},{"key":"2021122309534833300_B2","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1161\/CIRCRESAHA.113.300218","article-title":"Emerging paradigms in cardiomyopathies associated with cancer therapies","volume":"113","author":"Ky","year":"2013","journal-title":"Circ Res"},{"key":"2021122309534833300_B3","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1200\/JCO.2012.45.2938","article-title":"Late cardiac effects of cancer treatment","volume":"30","author":"Lenihan","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122309534833300_B4","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/1471-2407-10-337","article-title":"Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials","volume":"10","author":"Smith","year":"2010","journal-title":"BMC Cancer"},{"key":"2021122309534833300_B5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1158\/1078-0432.CCR-07-1033","article-title":"Cardiac toxicity in breast cancer survivors: Review of potential cardiac problems","volume":"14","author":"Bird","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2021122309534833300_B6","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.mcna.2012.07.008","article-title":"Breast cancer therapies and cardiomyopathy","volume":"96","author":"Groarke","year":"2012","journal-title":"Med Clin North Am"},{"key":"2021122309534833300_B7","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1161\/01.CIR.0000080946.42225.4D","article-title":"ACC\/AHA\/ASNC Guidelines for the clinical use of cardiac radionuclide imaging\u2014Executive summary: A report of the American College of Cardiology\/American Heart Association task force on practice guidelines (ACC\/AHA\/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging)","volume":"108","author":"Klocke","year":"2003","journal-title":"Circulation"},{"key":"2021122309534833300_B8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/00000421-200108000-00027","article-title":"Is MUGA scan necessary in patients with low-risk breast cancer before doxorubicin-based adjuvant therapy? Multiple gated acquisition","volume":"24","author":"Sabel","year":"2001","journal-title":"Am J Clin Oncol"},{"key":"2021122309534833300_B9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.clbc.2011.07.006","article-title":"Routine cardiac evaluation in patients with early-stage breast cancer before adjuvant chemotherapy","volume":"12","author":"Jeyakumar","year":"2012","journal-title":"Clin Breast Cancer"},{"key":"2021122309534833300_B10","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1200\/JOP.2012.000682","article-title":"Utility of routine left ventricular ejection fraction measurement before anthracycline-based chemotherapy in patients with diffuse large B-cell lymphoma","volume":"8","author":"Conrad","year":"2012","journal-title":"J Oncol Pract"},{"key":"2021122309534833300_B11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/10428194.2014.883072","article-title":"A single-institution analysis of the utility of pre-induction ejection fraction measurement in patients newly diagnosed with acute myeloid leukemia","volume":"56","author":"Bryant","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2021122309534833300_B12","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","article-title":"Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer","volume":"30","author":"Romond","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2015-0449","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2015-0449","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/6\/666\/41875663\/oncolo_21_6_666.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/6\/666\/41875663\/oncolo_21_6_666.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T04:36:46Z","timestamp":1640320606000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/21\/6\/666\/6401457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,22]]},"references-count":12,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,4,22]]},"published-print":{"date-parts":[[2016,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2015-0449","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,6,1]]},"published":{"date-parts":[[2016,4,22]]}}}